BAP1 and small cell lung carcinoma: In this current study, we identified and characterized a next-generation BAP1 inhibitor (iBAP-II) with higher activity and specificity, and further determined its impact on BAP1-dependent transcriptional programming and SCLC cell viability in vitro and in vivo.